Ísrael - hebreska - Ministry of Health

נוגם תמרוקים בעמ - שמש ינרק הנגה

Ísrael - hebreska - Ministry of Health

נוגם תמרוקים בעמ - צמצום קמטים וקמטוטים

Ísrael - hebreska - Ministry of Health

נוגם תמרוקים בעמ - סרום לפנים,צוואר ואיזור המחשוף

Ísrael - hebreska - Ministry of Health

נוגם תמרוקים בעמ - סרום לעיניים

Ísrael - hebreska - Ministry of Health

cts ltd - levetiracetam - תמיסה - levetiracetam 100 mg/ml - levetiracetam - levetiracetam - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. keppra is indicated as adjunctive therapy - in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ísrael - hebreska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ísrael - hebreska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ísrael - hebreska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 1000 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ísrael - hebreska - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 250 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ísrael - hebreska - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 500 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.